Last reviewed · How we verify
Intraanal NRL001 Gel 2 strengths
Intraanal NRL001 Gel 2 strengths is a Small molecule drug developed by Norgine. It is currently in Phase 1 development. Also known as: methoxamine gel 3.0%, 1.0%.
NRL001 is an investigational intraanal gel developed by Norgine for the treatment of anal conditions. Currently in early clinical development, it has completed a Phase 1 trial assessing safety and dose response. No FDA label is available, and further studies are needed to establish efficacy and safety.
At a glance
| Generic name | Intraanal NRL001 Gel 2 strengths |
|---|---|
| Also known as | methoxamine gel 3.0%, 1.0% |
| Sponsor | Norgine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraanal NRL001 Gel 2 strengths CI brief — competitive landscape report
- Intraanal NRL001 Gel 2 strengths updates RSS · CI watch RSS
- Norgine portfolio CI
Frequently asked questions about Intraanal NRL001 Gel 2 strengths
What is Intraanal NRL001 Gel 2 strengths?
Intraanal NRL001 Gel 2 strengths is a Small molecule drug developed by Norgine.
Who makes Intraanal NRL001 Gel 2 strengths?
Intraanal NRL001 Gel 2 strengths is developed by Norgine (see full Norgine pipeline at /company/norgine).
Is Intraanal NRL001 Gel 2 strengths also known as anything else?
Intraanal NRL001 Gel 2 strengths is also known as methoxamine gel 3.0%, 1.0%.
What development phase is Intraanal NRL001 Gel 2 strengths in?
Intraanal NRL001 Gel 2 strengths is in Phase 1.
Related
- Manufacturer: Norgine — full pipeline
- Also known as: methoxamine gel 3.0%, 1.0%
- Compare: Intraanal NRL001 Gel 2 strengths vs similar drugs
- Pricing: Intraanal NRL001 Gel 2 strengths cost, discount & access